CVD policy in 4 minutes

Coordinated Vulnerability Disclosure Generator

FDA Section 524B requires a documented vulnerability disclosure process. Fill in the blanks; get a publish-ready policy aligned to ISO/IEC 29147 and CISA's CVD guidance.

Reviewed by

Christian Espinosa

Founder & CEO, Blue Goat Cyber

Last reviewed May 21, 2026

Company name

Product / product family in scope

Security contact email

PGP key URL (optional)

In-scope assets (optional, comma separated)

Acknowledge within (days)

Triage within (days)

Remediate within (days)

Public disclosure window (days)

What you'll see after you submit

Inputs become a publish-ready CVD policy and SLA timeline

MilestoneTimeline infographic: acknowledgement → triage → fix → public disclosure SLAs.
ISO/IEC 29147-structured policy text with your contact details and PGP fingerprint baked in.
Copy-to-clipboard handoff for legal review and posting at /security or /.well-known/security.txt.
Direct alignment notes for FDA §524B 'coordinated vulnerability disclosure process' requirement.

Common misconceptions

What teams usually get wrong

Myth: A security@ inbox is enough to satisfy FDA's CVD requirement.

Reality: §524B requires a documented process: intake, triage SLAs, coordination with reporters, and a public-facing policy. An inbox without a policy is a deficiency.
Myth: We can wait until a researcher reports something to publish a policy.

Reality: FDA explicitly looks for the published CVD policy in the premarket submission. No policy → an AI letter on day 60.
Myth: Bug bounty = CVD program.

Reality: Bounties pay for findings; CVD governs how findings are handled, disclosed, and reported to FDA. You can have CVD without a bounty, but not the other way around.
Myth: Safe-harbor language is boilerplate.

Reality: It's the single most-cited reason researchers will or won't report. Generic legalese chills disclosure; ISO 29147-aligned safe-harbor language unlocks it.